Harmony Biosciences Acquires Asset with Novel Mechanism of Action for the Potential Treatment of Narcolepsy and other Rare Neurological Diseases
Harmony Biosciences recently announced the acquisition of HBS-102, a potential first-in-class molecule with a novel mechanism of action, from ConSynance Therapeutics, Inc. HBS-102 is a Melanin Concentrating Hormone Receptor 1 (MCHR1) antagonist that has the potential to offer a novel approach to the treatment of narcolepsy including the symptoms of Rapid Eye Movement (REM) sleep...
PWSA | USA and FPWR Share Combined FDA Patient Listening Session Summary
On June 17, 2021, representatives from PWSA | USA, FPWR and experts in the field of Prader-Willi syndrome research met with the FDA’s Center for Drug Evaluation and Research to discuss issues related to PWS clinical trials. The purpose of this meeting was to promote dialogue between PWSA | USA, FPWR and members of the...
Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study
On behalf of Radius Health, Inc: Boston, Mass., July 22, 2021 — Radius Health, Inc. announced Wednesday, July 21, 2021 that it has recently received the written meeting minutes from a June Type C meeting held with the U.S. Food and Drug Administration (FDA) regarding RAD011, a synthetic cannabidiol oral solution. RAD011 is initially to...
Billions in Funding Allocated to Schools Nationwide to Help Students with Disabilities
More than $3 billion in funding is set to be dispersed to schools around the country to meet the needs of students with disabilities after the fallout from COVID-19. Some of the funding will be used to support:Special Education programs for students between 3- and 21-years-oldPreschool offerings, specifically for infants and toddlers with disabilities